晚期眼内视网膜母细胞瘤基于就诊特征与治疗方式的转移性死亡:一项多中心登记研究
该国际多中心登记回顾性研究纳入1841例晚期眼内视网膜母细胞瘤患者,按AJCC cT2/cT3亚类及AJCC-OOTF大小分组评估转移性死亡风险。结果显示cT亚类越高、大小分组越大,转移死亡风险越高;初始眼球摘除术的5年生存率最高(96%)。
要点
- cT3c(青光眼)、cT3d(眼内出血)、cT3e(眶蜂窝织炎)的转移死亡风险分别高于cT2a(HR 4.9、14.0、19.6)。
- AJCC-OOTF大小分组3和4的转移死亡风险高于分组1(HR 10.0和41.1)。
- 初始眼球摘除术5年生存率96%,高于全身化疗后二次摘除(89%)及化疗保眼(90%)。
核心结论
- AJCC-RB cT2和cT3亚类及基于大小的AJCC-OOTF分组3(>2/3眼球体积)和4(弥漫浸润型RB)对晚期眼内RB的转移性死亡提供了稳健的临床风险分层。
- 初始眼球摘除术为晚期眼内RB患者提供了最高的生存率。
研究设计与样本
- 国际、多中心、基于登记的回顾性病例系列。
- 共纳入1841例晚期RB患者。
主要发现
- 患者层面AJCC临床亚类的5年Kaplan-Meier累积生存率:cT2a 98%、cT2b 96%、cT3a 88%、cT3b 95%、cT3c 92%、cT3d 84%、cT3e 75%。
- 按治疗方式的5年生存率:初始眼球摘除术96%、全身化疗后二次眼球摘除89%、全身化疗保眼90%。
- 转移性死亡风险随cT亚类升高而增加(P<0.001)。
- Cox回归显示cT3c(HR 4.9;P=0.011)、cT3d(HR 14.0;P<0.001)、cT3e(HR 19.6;P<0.001)的转移死亡风险高于cT2a;全身化疗后二次摘除(HR 3.3;P<0.001)和保眼治疗(HR 4.9;P<0.001)的风险高于初始眼球摘除术。
- AJCC-OOTF大小分组1至4的5年生存率分别为99%、96%、94%、83%,转移死亡风险随分组增大而增加(P<0.001);分组3(HR 10.0;P=0.002)和分组4(HR 41.1;P<0.001)的风险高于分组1。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate presenting features, tumor size, and treatment methods for risk of metastatic death due to advanced intraocular retinoblastoma (RB). DESIGN: International, multicenter, registry-based retrospective case series. PARTICIPANTS: A total of 1841 patients with advanced RB. METHODS: Advanced RB was defined by 8th edition American Joint Committee on Cancer (AJCC) categories cT2 and cT3 and new AJCC-Ophthalmic Oncology Task Force (OOTF) Size Groups (1: < 50% of globe volume, 2: > 50% but < 2/3, 3: > 2/3, and 4: diffuse infiltrating RB). Treatments were primary enucleation, systemic chemotherapy with secondary enucleation, and systemic chemotherapy with eye salvage. MAIN OUTCOME MEASURES: Metastatic death. RESULTS: The 5-year Kaplan-Meier cumulative survival estimates by patient-level AJCC clinical subcategories were 98% for cT2a, 96% for cT2b, 88% for cT3a, 95% for cT3b, 92% for cT3c, 84% for cT3d, and 75% for cT3e RB. Survival estimates by treatment modality were 96% for primary enucleation, 89% for systemic chemotherapy and secondary enucleation, and 90% for systemic chemotherapy with eye salvage. Risk of metastatic mortality increased with increasing cT subcategory (P < 0.001). Cox proportional hazards regression analysis confirmed a higher risk of metastatic mortality in categories cT3c (glaucoma, hazard ratio [HR], 4.9; P = 0.011), cT3d (intraocular hemorrhage, HR, 14.0; P < 0.001), and cT3e (orbital cellulitis, HR, 19.6; P < 0.001) than in category cT2a and with systemic chemotherapy with secondary enucleation (HR, 3.3; P < 0.001) and eye salvage (HR, 4.9; P < 0.001) than with primary enucleation. The 5-year Kaplan-Meier cumulative survival estimates by AJCC-OOTF Size Groups 1 to 4 were 99%, 96%, 94%, and 83%, respectively. Mortality from metastatic RB increased with increasing Size Group (P < 0.001). Cox proportional hazards regression analysis revealed that patients with Size Group 3 (HR, 10.0; P = 0.002) and 4 (HR, 41.1; P < 0.001) had a greater risk of metastatic mortality than Size Group 1. CONCLUSIONS: The AJCC-RB cT2 and cT3 subcategories and size-based AJCC-OOTF Groups 3 (> 2/3 globe volume) and 4 (diffuse infiltrating RB) provided a robust stratification of clinical risk for metastatic death in advanced intraocular RB. Primary enucleation offered the highest survival rates for patients with advanced intraocular RB.
引用
- Tomar AS, Finger PT, Gallie B, et al. Metastatic Death Based on Presenting Features and Treatment for Advanced Intraocular Retinoblastoma: A Multicenter Registry-Based Study. Ophthalmology. 2022. PMID: 35500608. doi:10.1016/j.ophtha.2022.04.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。